Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma

International Journal of Oncology

Volumn 39, Issue 2, 2011, Pages 425-431

  Liu, Yong Yu ^a   Patwardhan, Gauri A ^a   Xie, Ping ^b   Gu, Xin ^c   Giuliano, Armando E ^d   Cabot, Myles C ^d  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^c Louisiana State University School of Medicine Shreveport   (United States)

^d JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Drug resistance; Glucosylceramide synthase; Metastasis

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BLADDER; BREAST CARCINOMA; BREAST FIBROADENOMA; CONTROLLED STUDY; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; LIVER; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH; TESTIS; TISSUE DISTRIBUTION; UTERINE CERVIX;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSYLTRANSFERASES; HELA CELLS; HL-60 CELLS; HUMANS; K562 CELLS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 79960006801     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1052     Document Type: Article

References (42)

1. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
2. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
3. Moreno-Aspitia A and Perez EA: Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31: 1619-1640, 2009.
4. SEER: Cancer Statistics Review, 1975-2006. http://seer.cancer.gov/csr/ 1975-2006.: accessed 2009.
5. Bradley G and Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223-233, 1994. (Pubitemid 24220007)
6. Shabbits JA, Krishna R and Mayer LD: Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1: 585-594, 2001. (Pubitemid 34685466)
7. Makin G and Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 11: S22-S26, 2001.
8. Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6: 350-354, 2006. (Pubitemid 44026037)
9. Liu YY, Han TY, Giuliano AE and Cabot MC: Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730, 2001. (Pubitemid 32245990)
10. Senchenkov A, Litvak DA and Cabot MC: Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 93: 347-357, 2001. (Pubitemid 32229379)
11. Reynolds CP, Maurer BJ and Kolesnick RN: Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206: 169-180, 2004. (Pubitemid 38317287)
12. Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616, 2004. (Pubitemid 39025055)
13. Kok JW and Sietsma H: Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 5: 375-382, 2004. (Pubitemid 38559347)
14. Hannun YA: The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269: 3125-3128, 1994.
15. Jeckel D, Karrenbauer A, Burger KN, van Meer G and Wieland F: Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J Cell Biol 117: 259-267, 1992.
16. Kolesnick R and Hannun YA: Ceramide and apoptosis. Trends Biochem Sci 24: 224-225; author reply 227, 1999.
17. Ogretmen B and Hannun YA: Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 4: 368-377, 2001. (Pubitemid 34746871)
18. Kolesnick R and Fuks Z: Radiation and ceramide-induced apoptosis. Oncogene 22: 5897-5906, 2003. (Pubitemid 37176710)
19. Kolesnick R, Altieri D and Fuks Z: A CERTain role for ceramide in taxane-induced cell death. Cancer Cell 11: 473-475, 2007. (Pubitemid 46856911)
20. Liu YY, Han TY, Giuliano AE and Cabot MC: Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274: 1140-1146, 1999.
21. Ogretmen B, Schady D, Usta J et al: Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 276: 24901-24910, 2001.
22. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y and Cabot MC: Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp Cell Res 252: 464-470, 1999. (Pubitemid 29530276)
23. Gouaze V, Yu JY, Bleicher RJ et al: Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639, 2004. (Pubitemid 39193742)
24. Liu YY, Yu JY, Yin D, et al: A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22: 2541-2551, 2008. (Pubitemid 351948671)
25. Patwardhan GA, Zhang QJ, Yin D, et al: A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS One 4: e6938, 2009.
26. Liu YY, Gupta V, Patwardhan GA, et al: Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9: 145, 2010.
27. Liu YY, Patwardhan GA, Bhinge K, Gupta V, Gu X and Jazwinski SM: Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 71: 2276-2285, 2011.
28. Itoh M, Kitano T, Watanabe M, et al: Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 9: 415-423, 2003. (Pubitemid 36109759)
29. Xie P, Shen YF, Shi YP, et al: Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32: 475-480, 2008. (Pubitemid 351295915)
30. Jones J, Otu H, Spentzos D, et al: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730-5739, 2005. (Pubitemid 41170297)
31. Kroon BK, Leijte JA, van Boven H, et al: Microarray gene-expression profiling to predict lymph node metastasis in penile carcinoma. BJU Int 102: 510-515, 2008. (Pubitemid 352032842)
32. Ruckhaberle E, Karn T, Hanker L, et al: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 135: 81-90, 2009.
33. Juul N, Szallasi Z, Eklund AC, et al: Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11: 358-365, 2010.
34. Sun CC, Zhang Z, Zhang SY, Li J, Li ZL and Kong CZ: Up-regulation of glucosylceramide synthase in urinary bladder neoplasms. Urol Oncol (In press).
35. Hannun YA and Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150, 2008. (Pubitemid 351158911)
36. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL and Cabot MC: Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18: 475-480, 1998. (Pubitemid 28174859)
37. Lavie Y, Cao H, Bursten SL, Giuliano AE and Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271: 19530-19536, 1996. (Pubitemid 26271630)
38. Taki T, Ishikawa D, Ogura M, Nakajima M and Handa S: Ganglioside GDlalpha functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue. Cancer Res 57: 1882-1888, 1997.
39. Kovbasnjuk O, Mourtazina R, Baibakov B, et al: The glycosphingo-lipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA 102: 19087-19092, 2005. (Pubitemid 43049570)
40. Kolmakova A, Rajesh M, Zang D, Pili R and Chatterjee S: VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconj J 26: 547-558, 2009.
41. Patwardhan G, Gupta V, Huang J Gu X and Liu YY Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol 80: 72-79, 2010.
42. Zhang X, Li J Qiu Z, Gao P, Wu X and Zhou G: Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi). Cancer Biol Ther 8: 1117-1121, 2009.